Generic Oncology Sterile Injectables Market - Size, Share, Trends, and Forecast to 2027

The global generic oncology sterile injectable market By Product Type (Chemotherapy, Monoclonal Antibodies, Cytokines, and Peptide Hormones), By Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 8.9 billion in 2016 and is projected to expand at a CAGR of 11.4% over the forecast period (2017-2025), as highlighted in a new report published by Coherent Market Insights. Rising incidence and prevalence of multiple cancer such as ovarian cancer, breast cancer, lung cancer, and pancreatic cancer and growing need for treatment are expected to be major driving factors for generic oncology sterile injectable market growth over the forecast period.

According to the World Health Organization (WHO), in 2012, around 14 million new cases of cancer were reported. Moreover, according to the WHO, cancer is a second leading cause of mortality, worldwide. Furthermore, according to the Cancer Research UK, in 2012, over 4 in 10 of new cases of cancer are breast, lung, bowel or prostate cancer. Moreover, according to the Cancer Research UK, in 2014, around 356,860 new cases of cancer were estimated in the U.K. Furthermore, according to the Centers for Disease Control and Prevention (CDC), in 2015, approximately 21.1 million adults were diagnosed with cancer in the U.S. Therefore, rising high prevalence of cancer requires proper treatment management for better patient outcome. This is expected to aid in generic oncology sterile injectable market growth over the forecast period.

In May, 2017, India based Dr. Reddy's Laboratories received U.S. Food and Drug Administration (FDA) approval for its Doxorubicin Hydrochloride Liposome Intravenous injection in the U.S. market. The product is a generic version of Doxil, a chemotherapy drug used in stopping cancerous cell growth. It can be used for treatment of multiple myeloma, ovarian cancer, and AIDS-related Kaposi's sarcoma. This U.S. FDA authorization was an outcome of collaboration result of Natco Pharma Limited with Dr. Reddy's Laboratory. Therefore, development of oncology specific generic sterile injectables and strategic collaborations by manufacturers is expected to support growth of the generic oncology sterile injectables market over the forecast period.

Browse 28 Market Data Tables and 25 Figures spread through 140 Pages and in-depth TOC on generic oncology sterile injectable market by product type (chemotherapy, monoclonal antibodies, cytokines, peptide hormones), by disease indication (ovarian cancer, breast cancer, lung cancer, pancreatic cancer, and others), by distribution channel (hospital pharmacies, retail pharmacies and online pharmacies), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2025

To know the latest trends and insights prevalent in the generic oncology sterile injectable market, click the link below:

https://www.coherentmarketinsights.com/market-insight/generic-oncology-sterile-injectables-market-562

Key Takeaways of the Generic Oncology Sterile Injectable Market:

The global generic oncology sterile injectables market is expected to expand at a CAGR 11.4% over the forecast period (2017-2025) due to rampant increase in incidence rate of cancer and other chronic conditions
Among product types, monoclonal antibodies held the dominant position in the global generic oncology sterile injectables market in 2016. This is attributed to properties of monoclonal antibody to specifically target the cancer cell and these have less side-effects compare to chemotherapy.
Among disease indications, other cancers (melanoma, brain cancer, prostate cancer, etc.) is a major disease indication segment in the global generic oncology sterile injectable market, as there have been a spur in product launches for these cancer types in the recent past
Some of the key players in the global generic oncology sterile injectable market are Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.